{"entity":{"id":"rabacfosadine","kind":"drug","name":"Rabacfosadine","aka":["Tanovea","Tanovea-CA1","rabacfosadine for injection"],"tldr":"Rabacfosadine (Tanovea) is an intravenous drip for dogs with lymphoma, conditionally approved by the US Food and Drug Administration in 2016 and fully approved in 2021. It is a medicine for dogs and is not used in people.","summary":"Tanovea (rabacfosadine for injection) was conditionally approved by the FDA Center for Veterinary Medicine in December 2016 (as Tanovea-CA1) and received full approval on 15 July 2021 under NADA 141-545, sponsored by VetDC, Inc., for the treatment of lymphoma in dogs. The labelled regimen is 1 mg/kg by intravenous infusion every 21 days for up to five doses.\n\nThe effectiveness study randomised client-owned dogs with multicentric B-cell or T-cell lymphoma 3:1 to rabacfosadine or saline placebo. Median progression-free survival was 82 days against 21 days (P < 0.0001); in dogs with a complete or partial response it was 151 days. The commonest adverse reactions were diarrhoea, decreased appetite, vomiting, lethargy, weight loss and neutropenia. It is a veterinary medicine and has no human approval.","asOf":"2026-11-04","links":[{"label":"FDA Consumer Update: My Dog Has Cancer: What Do I Need to Know?","url":"https://www.fda.gov/consumers/consumer-updates/my-dog-has-cancer-what-do-i-need-know"},{"label":"FDA Freedom of Information Summary, NADA 141-545 Tanovea (approved 15 July 2021)","url":"https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11083"}],"tags":["veterinary","comparative-oncology"],"related":["idea-bio1-comparative-oncology-dogs","veterinary-and-comparative-oncology"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Tanovea","modality":"small molecule (nucleotide analogue)","mechanism":"A small molecule that mimics the nucleoside guanine; the FDA summary states it preferentially targets rapidly dividing lymphoma cells and interferes with their DNA synthesis, reducing proliferation and causing cell death.","approvals":[],"mechanismSteps":["Rabacfosadine looks like guanine, one of the building blocks of DNA","Fast-dividing lymphoma cells take it up while copying their DNA","It blocks DNA synthesis, so the cells stop dividing and die, and the swollen lymph nodes shrink"],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rabacfosadine/","neighbours":{"idea":[{"id":"idea-bio1-comparative-oncology-dogs","kind":"idea","name":"Pet dogs with spontaneous cancer as a bridge before human trials","route":"/ideas/idea-bio1-comparative-oncology-dogs/"}],"journal":[{"id":"veterinary-and-comparative-oncology","kind":"journal","name":"Veterinary and comparative oncology","route":"/journals/veterinary-and-comparative-oncology/"}]}}